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Purpose: To identify the effect of insufficient lymph node dissection (LND) on 
the survival of patients with pT2 gastric cancer. Materials and Methods: A total 
of 340 patients (120 patients with insufficient LND and others with D2 LND) who 
underwent gastrectomy for pT2 gastric cancer between January 2008 and Decem-
ber 2010 were included. Results: The incidence of preoperatively diagnosed early 
gastric cancer was higher and there were fewer metastatic lymph nodes (LNs) in 
the insufficient LND group than the D2 group, but there was no survival differ-
ence between two groups (p=0.365). Among the 89 patients with metastatic LNs 
after D2 LND, 13 patients (14.6%) had metastatic LNs at selected N2 stations 
(#10, 11, or 12a), but none of these patients were in the pN1 category. One patient 
had five metastatic LNs at station #11p with no metastatic LNs at any other sta-
tions. The number of metastatic LNs was identified as the only risk factor for LN 
metastasis at selected N2 stations by logistic regression. Conclusion: If a patient 
has pN0 or pN1 category after insufficient LND for pT2 gastric cancer, the surgery 
can be regarded as secure. However, for patients with pN2 or pN3 category, more 
careful examination is required.
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INTRODUCTION
Surgery is the only method for curing advanced gastric cancer (AGC).1 The depth 
of tumor invasion,1,2 the metastatic lymph node (LN) status, and R0 resection are 
the most important independent prognostic factors for gastric cancer (GC).3,4 
Therefore, adequate LN dissection (LND) during gastrectomy is vital for both ac-
curate tumor staging and achieving R0 resection during GC treatment. 
Although there have long been debates about the necessity of D2 LND for GC,5-8 
D2 LND is considered a standard procedure in GC surgery.9 A recent guideline 
recommended that gastrectomy with D1+ LND is sufficient for cases of early gas-
tric cancer (EGC), and D2 LND should be performed for AGC.10 When the tumor 
depth is indicative of EGC in the preoperative evaluation, surgeons usually per-
form less than D2 LND. However, sometimes patients who were considered to 
have EGC through preoperative evaluation can turn out to have AGC in the final 
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then the dissection was classified as insufficient LND. 
Stations #7, 8a, 9, 10, 11, and 12a were considered extra-
gastric LNs, or N2 stations. In this study, stations #10, 11, 
and 12a were designated as selected N2 stations (Fig. 2), 
because LND of stations #7, 8a, and 9 is routinely per-
formed in all GC surgeries with curative intent. 
According to Japanese guidelines for gastric cancer sur-
gery,10 all 340 patients who were finally diagnosed as pT2 
GC from our institution should undergo D2 LND. Howev-
er, 120 patients underwent insufficient LND due to the pa-
tients’ conditions and tumor underestimation in the preoper-
ative work-up. 
Evaluation of clinicopathological variables, surgical 
outcomes, and survival
We retrospectively studied clinicopathological factors such 
as age, sex, body mass index (BMI), various comorbidities, 
and preoperative diagnosis; perioperative factors including 
resection extent, approach methods, operative time, amount 
of blood loss, transfusion, postoperative hospital stay, and 
postoperative complications; and pathologic factors such as 
number of metastatic and retrieved LNs, tumor size, Bor-
rmann type, Lauren classification, histologic grade, and pN 
category. To evaluate the preoperative diagnosis of gastric 
cancer, we reviewed radiologic reports of computed tomog-
raphy (CT). If we found any comment about wall thickening 
in the gastric wall, it was determined to be AGC otherwise 
we consider it EGC. In addition, the presence of detectable 
lymph nodes was recorded. 
Laparoscopic or laparoscopic-assisted gastrectomy and 
robotic or robotic-assisted gastrectomy were considered 
minimally invasive surgeries (MISs). After gastrectomy, 
most patients were treated with adjuvant chemotherapy 
when necessary according to the patient’s final pathologic 
stages. Papillary and well to moderate differentiated tubular 
adenocarcinomas were classified as differentiated types; 
pathological results after surgery, and most of these patients 
(54.4-68.9%) were discovered to have cancer that was in-
vading the proper muscle layer (pT2).11,12 
When considering the possibility of remaining metastatic 
LNs and tumor downstaging, it would be insufficient to per-
form anything less than D2 LND in pT2 GC. Therefore, sur-
geons worry about the surgical adequacy and oncological 
effects of less than D2 LND, the insufficient LND, in pT2 
GC. In the present study, we evaluated the oncological safe-
ty and surgical curability of insufficient LND in pT2 GC.  
MATERIALS AND METHODS
　　　
Patient selection  
The medical records of patients who underwent gastrectomy 
for GC at Yonsei University Severance Hospital between 
January 2008 and December 2010 were reviewed, and 350 
patients were confirmed to have pT2 GC in their final patho-
logic reports. Among them, 10 patients were excluded for 
the following reasons: neo-adjuvant chemotherapy in 5 pa-
tients, palliative gastrectomy in 1 patient, and unclear medi-
cal records in 4 patients (Fig. 1). 
Definition of insufficient LND, insufficient D2 LND, 
and selected N2 stations  
The standard extent of LND for gastric cancer in our institu-
tion is D1+ for EGC, and D2 for AGC. D2 LND was de-
fined according to Japanese GC guidelines 201010,13 as fol-
lows. LND at stations #1, 3, 4sb, 4d, 5, 6, 7, 8a, 9, 11p, and 
12a was classified as D2 LND in distal gastrectomy, but if 
the surgeon skipped any station among #11p and/or 12a, 
then the dissection was defined as insufficient LND. For to-
tal gastrectomy, LND at stations #1, 2, 3, 4, 5, 6, 7, 8a, 9, 10, 
11p, 11d, and 12a was categorized as D2 LND, but if the 
surgeon skipped any station among #10, 11d, and/or 12a, 
Fig. 1. Schematic diagram of patient selection. Fig. 2. The location of selected N2 stations (#10, #11p, #11d, and #12a).
Pathologically confirmed  
pT2 (pm) gastric cancer:  
350 patients
Neoadjuvant chemotherapy: 5 patients
Palliative gastrectomy: 1 patient 
  (due to liver metastasis)
Unclassified: 4 patients
(both pathologic station and operative 
record were not available)
Less than D2 lymph node  
dissection: 120 patients
D2 lymph node dissection:  
220 patients
344 patients
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vival and the 95% confidence intervals (CI). To assess the 
difference in survival between the two groups, the log rank 
test and Tarone-Ware test were applied. In addition, Cox 
proportional hazard model was applied with and without 
adjustment to estimate hazard ratios (HR). In all cases, a p-
value of less than 0.05 was considered a rejection of the 
null hypothesis. The statistical analyses were performed us-
ing IBM SPSS 20.0 (SPSS Inc., Chicago, IL, USA), and 
the Kaplan-Meier graph was created using R version 2.13.0 
(R Foundation for Statistical Computing, Vienna, Austria). 
 
RESULTS
 
Patient demographics
The demographics of the patients were similar between the 
two groups (Table 1). The mean age of patients was ap-
proximately 59 years in both groups, and the mean BMI 
was approximately 23 kg/m2. There were no significant dif-
ferences in the distribution of the type of comorbidities, 
American Society of Anesthesiologists score, and previous 
history of abdominal surgery. Insufficient LND was associ-
and mucinous carcinoma, signet-ring cell carcinoma, and 
poorly differentiated tubular adenocarcinoma were classi-
fied as undifferentiated types. Pathological stage evaluation 
was based on the seventh edition of the International Union 
Against Cancer Classification.14
Any death, regardless of cause, was recorded and reflect-
ed in the overall survival (OS) during follow-up. To eluci-
date the risk factors of LN metastasis at selected N2 sta-
tions (the difference of the extent of LND between two 
groups), the data of patients with information about metas-
tasis at each LN station were analyzed. In addition, the pat-
tern of recurrence after gastrectomy in each group was 
evaluated. 
Statistical analysis
For continuous variables, independent t-tests were used, and 
chi-square tests or Fisher’s exact tests were adopted for di-
chotomous variables as appropriate. A binary logistic re-
gression model was applied to calculate the odds ratio (OR) 
of LN metastasis at selected N2 station, and the OR of per-
forming insufficient LND. The Kaplan-Meier method was 
used to report survival curves and estimate the mean sur-
Table 1. Patient Demographics 
Insufficient LND (n=120) D2 LND (n=220) p value
Age (mean±SD)   58.7±12.3   59.6±11.8 0.663
Sex (M/F) 82/38 148/72 0.842
BMI (mean±SD) 23.2±3.1 23.5±3.0 0.939
ASA score (1/2/3)    87/28/5 138/77/5 0.064
Comorbidities (yes/no)
    HTN 31/89 72/148 0.186
    DM   15/105 26/194 0.854
    Pulmonary     3/117   7/213 0.722
    Cardio   10/110 10/210 0.156
    CVA     5/115 15/205 0.321
    Pulmonary tuberculosis   10/110 18/202 0.961
    Hepatic     7/113 17/203 0.515
    Nephro     6/114   7/213 0.404
    Others   17/103 43/177 0.214
Previous abdominal surgery (yes/no) 27/93 38/182 0.241
EGD* <0.001
    EGC 56   50
    AGC 60 158
CT*
    EGC 44   41 0.001
    AGC 69 159
    Detected LNs 30   82 0.021
LND, lymph node dissection; BMI, body mass index; ASA, American Society of Anesthesiologists; HTN, hypertension; DM, diabetes mellitus; CVA, cere-
brovascular accident; EGC, early gastric cancer; AGC, advanced gastric cancer; EGD, esophagogastroduodenoscopy; CT, computed tomography; LN, lymph 
node; GC, gastric cancer; SD, standard deviation.
*Data were not available for some patients who were diagnosed with GC in other hospitals.
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the OR of performing insufficient LND was 2.5 (p=0.01). 
In addition, LNs were more frequently detected from CT 
scans in D2 LND than insufficient LND (p=0.021).
ated with the preoperative diagnosis. When a patient was 
diagnosed with EGC by preoperative endoscopy, the OR 
was 3.0 (p<0.001), and if CT was used to diagnose EGC, 
Table 2. The Perioperative Outcomes of the Insufficient LND and D2 LND Groups 
Insufficient LND 
(n=120)
D2 LND 
(n=220)
Unadjusted 
p value
Adjusted 
p value*
OP type (%) 0.059 0.082
    TG   41 (34.2)   54 (24.5)
    DG   79 (65.8) 166 (75.5)
Modality (%) 0.027 -
    MIS   40 (33.3)   49 (22.3)
    Open   80 (66.7) 171 (77.7)
OP time (min) 180.3±64.1 172.8±59.3 0.316 0.538
Hospital Stay   9.0±5.7 10.4±8.8 <0.001 0.309
Blood loss   109.6±121.6   122.5±147.9 0.018 0.799
Transfusion 4/116 14/206 0.233 0.342
Complications (%)   21 (17.5)   48 (21.8) 0.344 0.467
    Leak 3   4
    Intra-abdominal bleeding 0   2
    Pulmonary complication 8 15
    UTI 1   2
    Wound complication 6 11
    Abnormal fluid collection 3 16
    Pancreatitis 1   1
Retrieved LNs  41.2±16.4 41.4±15.8 0.599 0.913
Metastatic LNs  1.2±3.2 2.4±4.8 <0.001 0.022
Histology grade (%) 0.700 0.468
    Differentiated   44 (36.7)   90 (40.9)
    Undifferentiated   71 (59.2) 123 (55.9)
    Others†   5 (4.1)   7 (3.2)
Lauren classification (%) 0.440 0.297
    Intestinal   63 (52.5) 128 (58.2)
    Diffuse 48 (40)   83 (37.7)
    Mixed   7 (5.8)   6 (2.7)
    Unclassified   2 (1.7)   3 (1.4)
Borrmann type (%) 0.713 0.701
    I, II   35 (29.2)   85 (38.6)
    III, IV   69 (57.5) 151 (68.6)
Sizes (mm) (%) 0.188 0.127
    ≤20   37 (30.8)   54 (24.5)
    21-30 42 (35)   69 (31.4)
    ≥31    41 (34.2)   97 (44.1)
pN category (%) 0.009 0.002
    pN0 (0)   83 (69.2) 117 (53.2)
    pN1 (1-2)   22 (18.3)   42 (19.1)
    pN2 (3-6)   9 (7.5)   32 (14.5)
    pN3 (7) 6 (5)   29 (13.2)
LND, lymph node dissection; OP, operative; LN, lymph node; UTI, urinary tract infection; MIS, minimally invasive surgery; TG, total gastrectomy; DG, distal 
gastrectomy.
*Adjusted for age, sex, and operative modality.
†Lymphoepithelioma-like carcinoma, medullary carcinoma, or neuroendocrine tumor.
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creased to 1.56 (95% CI: 0.60-4.08), but this value was not 
statistically significant (p=0.366). The result was similar 
when the HR was adjusted by pN category and preoperative 
diagnosis based on computed tomography and esophago-
gastroduodenoscopy (HR: 1.72, 0.64-4.65, p=0.282). In 
terms of disease free survival, the HR adjusted by age, sex, 
and pN category was 0.82 (95% CI: 0.29-2.30, p=0.709). 
Characteristics of patients with metastatic LNs at 
selected N2 stations
Among the 103 patients with metastatic LNs after D2 
LND, precise information regarding the presence of metas-
tasis at each LN station was available for 89 patients. Thir-
teen of these patients (14.6%) had any metastatic LN at se-
lected N2 stations (#10, 11, or 12a). The characteristics of 
Perioperative outcomes
The perioperative outcomes are presented in Table 2. 
There were 41 cases (34.2%) of total gastrectomy in the 
insufficient LND group and 54 cases (24.5%) in the D2 
LND group. MISs were more frequently performed in the 
insufficient LND group than in the D2 LND group (33.3% 
vs. 22.3%, p=0.027). The operative time (180.3 min vs. 
172.8 min), the incidence of transfusion (3.4% vs. 6.8%), 
and the incidence of postoperative complications were 
similar between the two groups. The length of hospital stay 
(9.0 days vs. 10.4 days) and the amount of blood loss 
(109.6 mL vs. 122.5 mL) appeared to be higher in the D2 
LND group than in the insufficient LND group, but the 
differences did not reach statistical significance after ad-
justing for age, sex, and operative modality (p=0.309 and 
0.799, respectively). 
The distribution of microscopic and macroscopic find-
ings of tumors, and tumor size showed no difference be-
tween the two groups. The number of retrieved LNs was 
also similar between the two groups regardless of the extent 
of gastrectomy and the modality (open/MIS). The number 
of metastatic LNs was greater in the D2 LND group than in 
the insufficient LND group (1.2 vs. 2.4, p=0.022), and con-
sequently, the pN category was higher in the D2 LND 
group than in the insufficient LND group (p=0.002).  
Survival analysis
After gastrectomy, no in-hospital mortality was identified, 
and the median follow-up duration was 31 months for OS 
and 29.5 months for recurrence. During follow-up, 22 pa-
tients died (7 patients in the insufficient LND group and 15 
patients in the D2 LND group); among them, 14 patients 
died because of GC, and the other patients died from other 
causes such as pneumonia, sudden cardiac arrest, and other 
cancers. Five patients were identified to have recurrence in 
the insufficient LND group as well as 23 patients in the D2 
LND group - detailed recurrence patterns are shown in Ta-
ble 3. The mean survival duration of the insufficient LND 
group was 51.2 months (95% CI: 49.2-53.2), compared 
with 52.0 months in the D2 LND group (95% CI: 50.6-53.5). 
The total OS was not different between the two groups (log 
rank test p-value: 0.946, Tarone-Ware test p-value: 0.811) 
(Fig. 3). In addition, there was no statistical difference be-
tween the two groups when analyzed according to pN cate-
gory (Fig. 4). In Cox regression analysis, the unadjusted 
HR for OS after insufficient LND was 0.969 (p=0.946). Af-
ter adjustment for age, sex, and pN category, the HR in-
Fig. 3. Kaplan-Meier curves of overall survival in each group.
Table 3. Cause of the Death and Pattern of Recurrence after 
Gastrectomy
Insufficient 
LND (n=120)
D2 LND (N2 meta)†
(n=220)
Cause of death
    Gastric cancer related 3 11 (1)
    Others 4   4 (1)
    Total patients 7 15 (2)
Pattern of recurrence
    Remnant stomach 2   5 (1)
    Lymph node 1   9 (4)
    Liver 2   6 (1)
    Lung 1   3 (1)
    Bone 0   2 (2)
    Peritoneum 3 1
    Others* 1 1
    Total patients 5 23 (7)
LND, lymph node dissection.
*One adrenal metastasis in insufficient LND group, and one brain metas-
tasis in D2 LND group.
†Patients who had metastatic lymph nodes at selected N2 stations.
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mor depth in preoperative evaluation, and the incidence of 
focal invasion in pT2 GC was reported at 32.1%.11 There-
fore, preoperative EGC is occasionally diagnosed as AGC 
after surgical resection, whereas the opposite is observed in 
some cases. Because radical gastrectomy with D2 LND is 
considered a standard surgery for AGC, we evaluated the 
oncologic outcome and safety margin of insufficient LND 
in pT2 GC. 
In the present study, there was no LN metastasis at select-
ed N2 stations (#10, 11, or 12a) after D2 LND, which are 
not removed during insufficient LND, when the final patho-
logic results revealed pN0 or pN1 category. In other words, 
even if insufficient LND was performed in patients with 
pT2 GC, it appears to be a secure operation when the final 
pathological reports revealed pT2N0 and pT2N1 disease. 
Moreover, there were no differences in survival and recur-
rence between the patients who underwent insufficient LND 
and those who underwent D2 LND in the pN0 and pN1 
categories. 
The reason for skipped LN metastasis is not fully under-
stood, and the possible theories are as follows: 1) there may 
these patients are described in Table 4. All of the 103 pa-
tients had more than two metastatic lymph nodes (pN2-3 
category), and no patient was in the pN1 category (pN2 cat-
egory n=3; pN3 category n=10). Only one patient had met-
astatic LNs at station #10, and six and seven patients had 
metastatic LNs at stations #11 and #12a, respectively. One 
patient had metastatic LNs at both station #11 and #12a. 
One patient had five metastatic LNs at station #11p with no 
metastasis at other stations after distal gastrectomy. Logistic 
regression failed to reveal any risk factors for LN metasta-
sis at the selected N2 stations excluding the number of met-
astatic LNs (p<0.001) (Table 5).    
DISCUSSION
Although the diagnostic modalities and the accuracy of pre-
operative diagnosis for GC have been improved, the diag-
nostic accuracy for the depth of tumor invasion was reported 
as approximately 70-85%.15-18 Focal invasion of the tumor is 
considered to be one possible cause of underestimated tu-
Fig. 4. Kaplan-Meier curves of overall survival for each pN category.
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on selected N2 stations (#10, 11, or 12a) or pT2 GC.21,22 
Currently, it appears to be nearly impossible to determine 
whether insufficient LND for pT2 GC is secure for patients 
with pN2 or pN3 category after gastrectomy. In addition, 
the postoperative diagnosis will be not useful to prevent in-
sufficient LND in clinical practice. Therefore, surgeons 
should perform D2 LND whenever there is any intraopera-
tive suspicion of LNs metastasis or pathological diagnosis, 
even if the lesion was diagnosed as EGC in the preopera-
tive evaluation. 
In conclusion, insufficient LND in pT2 GC appears to be 
secure when the final pathologic results reveal to be in the 
pN0 and pN1 category. If the final pathologic results are in 
be remaining occult metastases that are undetected by patho-
logic examination; 2) the minor omentum has many lym-
phatic routes; 3) there may be only a few perigastric LNs19; 
and 4) although the location is extragastric, it is the first LN 
in the lymphatic drain system.20 In our data, among the 89 
patients with metastatic LNs after D2 LND, one patient 
(1.1%) displayed skipped LN metastasis at station #11p af-
ter distal gastrectomy and this patients had pN2 category 
(five metastatic LNs). 
Among patients in the pN2 and pN3 category, 9.4% (3/32) 
and 34.5% (10/29) of patients, respectively, had metastatic 
LNs at selected N2 stations (#10, 11, or 12a). If these 13 
patients had undergone insufficient LND, the metastatic 
LNs at the selected N2 stations would have remained after 
surgery. In these patients, insufficient LND cannot be con-
sidered adequate or R0 resection. However, there was no 
statistical difference in OS between the two groups among 
patients in the pN2 and pN3 category. 
Reoperation or chemotherapy could be recommended if 
elucidation of the risk factors of LN metastasis at selected 
N2 stations in patients who underwent insufficient LND is 
possible. However, our data did not reveal any risk factors 
of LN metastasis at selected N2 stations, excluding the num-
ber of metastatic LNs. Higher number of metastatic LNs 
was found to be associated with a higher risk of metastasis 
at selected N2 stations in the pN2, and pN3 category.
The major limitation of the present study is the study de-
sign. The retrospective design can create selection bias. 
Lower mean number of metastatic LNs in the insufficient 
LND group would represent a selection bias, which means 
the baseline characteristics of the insufficient LND group 
could be better than D2 LND group even though both group 
share same pT stage. In addition, no difference between OS 
and recurrence between two groups is unexpected. Even 
though the subgroup analyses by pN category also showed 
same results, the different baseline characteristics would af-
fect this result. The difference of dissected stations between 
the two groups varied only 1-3 (#11p and/or #12a for distal 
gastrectomy and #10 and/or #11d and/or #12a) and the re-
trieved LNs were similar in the two groups. Finally, the me-
dian follow up period was not over the line of 36 months. 
Since a 15 year follow up randomized controlled trial of 
disease specific survival between D1 and D2 LND showed 
an only 11% benefit for D2 LND,8 it is difficult to make 
concrete conclusions from this study. 
The authors of several recent reports discussed the risk of 
LN metastasis at extragastric regions, but they did not focus 
Table 4. The Characteristics of the 13 Patients Who Had 
Metastatic LNs at Selected N2 Stations (#10, 11, or 12a) af-
ter D2 LND 
Clinical variables Patient number 
Sex (%)
    Male 11 (84.6)
    Female   2 (15.4)
Age (median, range)   57 (34-77)
Borrmann type (%)
    I 1 (7.7)
    II   4 (30.8)
    III   8 (61.5)
Lauren classification (%) 
    Intestinal   9 (69.2)
    Diffuse   4 (30.8)
Histologic grade (%)
    Differentiated   3 (23.1)
    Undifferentiated 10 (76.9)
pN category (%)
    pN1 (1-2) 0 (0)
    pN2 (3-6)   3 (23.1)
    pN3 (7+) 10 (76.9)
The station of metastatic LNs 
    #10 1
    #11 6
    #12a   7*
Location of tumor (%)
    Upper third   2 (15.4)
    Middle third   3 (23.1)
    Lower third   8 (61.5)
Sizes (%)
    ≤20 (n=14)   2 (15.4)
    21-30 (n=28)   4 (30.8)
    ≥31 (n=47)   7 (53.8)
LND, lymph node dissection; LN, lymph node.
*One patient had metastatic LNs at both #11 and #12a.
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the pN2 and pN3 category, surgeons should carefully moni-
tor the patient during follow-up because of the high possi-
bility of remaining metastatic LNs at selected N2 stations. 
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